Last reviewed · How we verify

NCT03384602

MOVE for Your MIND

Completed NA Last updated 9 August 2024
What this trial tests

NA trial testing Dalcroze Eurhythmics Program in Cognitive Decline in 195 participants. Completed in 2 November 2022.

Timeline
14 December 2017
Primary endpoint
2 November 2021
2 November 2022

Quick facts

Lead sponsorUniversity of Zurich
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment195
Start date14 December 2017
Primary completion2 November 2021
Estimated completion2 November 2022
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University of Zurich

Who can join

70 and older, any sex, with Cognitive Decline or Fall. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Among the most promising interventions targeting both cognitive and functional decline, is Exercise. However, evidence regarding exercise interventions among seniors with cognitive impairment are inconclusive, likely due to challenges of recruitment and adherence. Alternatively, seniors with subjective cognitive decline (SCD), who are not yet meeting objective criteria of cognitive impairment, but have been shown to have twice the conversion rate to dementia compared with healthy seniors, are more likely to be motivated to participate and adhere to exercise interventions. Thus, exercise interventions in seniors with SCD may provide a window of opportunity for early prevention of dementia and falls. The investigators aim to test the effect of a group exercise (multi-task Jaques-Dalcroze Eurhythmics) and a simple home strength exercise program on change of cognitive function and the rate of falling among seniors with SCD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Safety and feasibility of a Dalcroze eurhythmics and a simple home exercise program among older adults with mild cognitive impairment (MCI) or mild dementia: the MOVE for your MIND pilot trial.
    Fischbacher M, Chocano-Bedoya PO, Meyer U, Bopp I, et al · · 2020 · cited 7× · PMID 32695433 · DOI 10.1186/s40814-020-00645-7

Verify or expand the search:

Other recruiting trials for Cognitive Decline

Currently open trials in the same condition.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03384602.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing